U.S. markets open in 4 hours 42 minutes
  • S&P Futures

    3,875.75
    -47.00 (-1.20%)
     
  • Dow Futures

    31,108.00
    -332.00 (-1.06%)
     
  • Nasdaq Futures

    11,765.25
    -170.25 (-1.43%)
     
  • Russell 2000 Futures

    1,752.90
    -19.90 (-1.12%)
     
  • Crude Oil

    108.90
    -0.69 (-0.63%)
     
  • Gold

    1,812.30
    -3.60 (-0.20%)
     
  • Silver

    21.33
    -0.21 (-0.97%)
     
  • EUR/USD

    1.0505
    +0.0040 (+0.38%)
     
  • 10-Yr Bond

    2.8860
    0.0000 (0.00%)
     
  • Vix

    32.22
    +6.12 (+23.45%)
     
  • GBP/USD

    1.2397
    +0.0055 (+0.45%)
     
  • USD/JPY

    127.8500
    -0.4470 (-0.35%)
     
  • BTC-USD

    29,105.63
    -689.70 (-2.31%)
     
  • CMC Crypto 200

    648.19
    -22.49 (-3.35%)
     
  • FTSE 100

    7,279.89
    -158.20 (-2.13%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

FDA Approves Zoetis' Solensia To Control Osteoarthritis Pain In Cats

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The FDA has approved Zoetis Inc's (NYSE: ZTS) Solensia (frunevetmab injection) to control the pain of osteoarthritis (OA) in cats, helping improve their mobility, comfort, and overall well-being.

  • Solensia, prescribed as a once-monthly injection administered in the veterinary clinic, controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain.

  • The drug is the first and only injectable monoclonal antibody (mAb) treatment for feline OA pain approved in the U.S.

  • After a single treatment, Solensia noticeably reduced OA pain. 77% of cat owners experienced seeing improvement in signs of pain after monthly treatment with Solensia in a 3-month study.

  • Also See: Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of .5B.

  • In comparison, 67% of cat owners experienced an improvement in their cat's pain signs in the placebo group.

  • Solensia was found to be well-tolerated: the most common side effects were vomiting and injection site pain.

  • Solensia is expected to be available to veterinarians in 2H of 2022. It is approved in the European Union and has been available to veterinarians since May 2021.

  • Price Action: ZTS shares closed lower by 2.73% at $207.00 on Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.